Half-year report · Q2
4543.TEDINET S100UOKT
Period2024-04-01 → 2024-09-30
Filed2024-11-11
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥508.7bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥921.9bn | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥443.9bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥87.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥66.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥85.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥140.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥66.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥106.4bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥63.2bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥50.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥1.75T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥1.83T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.75T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥438.8bn | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥504.3bn | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.31T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.33T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.26T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.31T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.33T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.26T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥194.9bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥187.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥100.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥146.3bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥53.6bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥38.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥81.5bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥36.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥65.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥62.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥30.0bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥42.57 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥71.5 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥33.63 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥42.56 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥71.47 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥33.62 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 75.0% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.5% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 72.1% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2024-04-01 → 2024-09-30 | ¥132m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥98.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥13.2bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥306.3bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥76.9bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥104.3bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥508.6bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥102.8bn |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2023-09-30 | ¥119m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.0bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥84.1bn |
| jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥10.6bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥265.7bn |
| jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥57.6bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥94.0bn |
| jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥443.8bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥76.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 637
| Item | Context | Value | Unit |
|---|---|---|---|
| Finance costs IFRS | Prior1YTDDuration | 1489000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 100000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 66428000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 306264000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 104278000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 98009000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 508552000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | 132000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 508685000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 76875000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 12744000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 13195000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 102816000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | 1168000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration | 103984000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -5084000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q2r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -5622000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReportableSegmentsMember | -10706000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReconcilingItemsMember | -194000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration | -10901000000 | JPY |
| Non recurring profit or loss IFRS | CurrentYTDDuration | -5366000000 | JPY |
| Operating profit loss IFRS | CurrentYTDDuration | 87716000000 | JPY |
| Finance income IFRS | CurrentYTDDuration | 1758000000 | JPY |
| Finance costs IFRS | CurrentYTDDuration | 4197000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | CurrentYTDDuration | -137000000 | JPY |
| Profit loss before tax IFRS | CurrentYTDDuration | 85140000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-11-11 | |
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第110期中(自 2024年４月１日 至 2024年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)テルモ株式会社 | |
| Company name in english cover page | FilingDateInstant | TERUMO CORPORATION | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長CEO 鮫島 光 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都渋谷区幡ケ谷二丁目44番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)03(3374)8111(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Text · Plus | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都新宿区西新宿三丁目20番２号 東京オペラシティタワー 49F | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)03(6742)8500(代表) | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Text · Plus | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E01630 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45430 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)テルモ株式会社 | |
| Filer name in english | FilingDateInstant | TERUMO CORPORATION | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |